<DOC>
	<DOCNO>NCT00129129</DOCNO>
	<brief_summary>This study evaluate safety immunogenicity GSK Biologicals ' Hib-MenCY-TT vaccine compare control group receive license Hib conjugate vaccine , administer 2 , 4 , 6 month age , compare license meningococcal serogroups A , C , Y , W-135 polysaccharide vaccine administer 3 5 year age . The safety immunogenicity booster dose Hib-MenCY-TT vaccine compare booster dose license Hib conjugate vaccine , administer 12 15 month age . The group prim Hib conjugate vaccine re-randomized 12-15 month age receive booster dose Hib-MenCY-TT booster dose Hib conjugate vaccine .</brief_summary>
	<brief_title>Comparison GSKBiologicals ' Hib-MenCY-TT Vaccine v Licensed Hib Conjugate Meningococcal Vaccine</brief_title>
	<detailed_description>The non-inferiority immunogenicity , safety , antibody persistence Hib-MenCY-TT vaccine compare ActHIB® , monovalent Hib conjugate vaccine license US . All subject vaccinate 2 , 4 , 6 , 12 15 month . The immunogenicity MenC MenY antigens summarize . MenC MenY immunogenicity compare Menomune® ( quadrivalent meningococcal A , C , Y , W-135 plain polysaccharide vaccine license US ) administer child 3 5 year age . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>For Groups A B Subjects investigator believe parents/guardians comply requirement protocol . Healthy male female , include , 6 12 week age time first vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Born gestation period 36 42 week . Infants receive previous dose hepatitis B vaccine receive 1 dose hepatitis B vaccine administer least 30 day prior enrollment . For Group C Subjects investigator believe parents/guardians comply requirement protocol . Healthy male female , include , 3 5 year age time first vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . For Groups A B Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol within 30 day first dose study vaccine ( ) . Previous vaccination Neisseria meningitidis , Haemophilus influenzae type b , diphtheria , tetanus , pertussis , poliovirus , and/or Streptococcus pneumoniae ; one previous dose hepatitis B vaccine . History Neisseria meningitidis , Haemophilus influenzae type b , diphtheria , tetanus , pertussis , hepatitis B , poliovirus , and/or Streptococcus pneumoniae disease . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination History allergic disease reaction likely exacerbate component vaccine ( ) , include dry natural latex rubber . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrollment . Administration immunoglobulins and/or blood product since birth plan administration study period . For Group C Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior vaccine dose . Planned administration/ administration vaccine foreseen study protocol within 30 day dose study vaccine . Previous vaccination Neisseria meningitidis . History Neisseria meningitidis disease . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination History allergic disease reaction likely exacerbate component vaccine , include dry natural latex rubber Major congenital defect serious chronic illness . Acute disease time enrollment . Administration immunoglobulins and/or blood product within 3 month precede vaccination plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Primary &amp; booster vaccination</keyword>
	<keyword>Infants</keyword>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Safety</keyword>
	<keyword>Children</keyword>
	<keyword>Hib disease</keyword>
	<keyword>Meningococcal disease</keyword>
</DOC>